Loading
A phase 3 trial testing Sitneprotafib in non-small-cell lung cancer, now recruiting.
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation is a phase 3 interventional study registered as NCT06416410, led by Allist Pharmaceuticals, and recruiting on the registry. Official title: An Open-label, Randomised, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation. Planned enrolment is 392 participants (estimated). The study started in 2024-08-07 and primary completion is expected in 2029-09-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sitneprotafib, Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant non-small-cell lung cancer.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Sitneprotafib, Glecirasib, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/